Keeping Track: US FDA Oncology Approvals For Ferring’s Gene Therapy Adstiladrin And Mirati’s Targeted Therapy Krazati

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Keeping Track Feature image

The US FDA’s approval of Ferring Pharmaceuticals’ bladder cancer gene therapy Adstiladrin just two weeks after the company took home an approval for the pioneering microbiome therapeutic Rebyota reshaped the Center for Biologics Evaluation and Research’s list of 2022 novel approvals by putting Switzerland-based Ferring on par with bluebird bio. The companies each received two novel approvals apiece.

More from US FDA Performance Tracker

More from Regulatory Trackers